Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate
Status:
Recruiting
Trial end date:
2028-07-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the effectiveness of darolutamide as part of
adjuvant androgen deprivation therapy (ADT) with a luteinising hormone releasing hormone
analogue (LHRHA) in men having radiation therapy for localised prostate cancer at very high
risk of recurrence.
Phase:
Phase 3
Details
Lead Sponsor:
University of Sydney
Collaborators:
Australian and New Zealand Urogenital and Prostate Cancer Trials Group Bayer Canadian Cancer Trials Group Cancer Trials Ireland Memorial Sloan Kettering Cancer Center Prostate Cancer Clinical Trials Consortium